Epstein-Barr virus-infected cells (EBV-infected cells)

Epstein-Barr virus (EBV)-infected cells represent a biological state where host cells, typically B-lymphocytes or epithelial cells, harbor the human herpesvirus 4 (HHV-4). Upon infection, the virus can enter a lytic cycle of replication or, more commonly, establish a lifelong latent infection by episomal persistence in the nucleus. In the latent state, EBV-infected cells express a limited set of viral products, including EBV-encoded small RNAs (EBERs) and latent proteins such as EBNA1, LMP1, and LMP2, which manipulate host cell signaling pathways to promote survival and proliferation. These processes can lead to the development of various malignancies, including Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma, as well as autoimmune conditions like multiple sclerosis. Therapeutic strategies do not target the virus in isolation but rather the EBV-infected cells themselves to prevent or treat associated diseases. Pharmacological intervention includes the use of nucleoside analogs like ganciclovir to inhibit lytic replication, though these are often ineffective against latent cells. More advanced approaches utilize monoclonal antibodies, such as rituximab, to deplete infected B-cell populations, or adoptive immunotherapies like Tabelecleucel (EBV-specific T-cells) that recognize and eliminate cells presenting specific EBV antigens. Because 'Epstein-Barr virus-infected cells' refers to a heterogeneous cell population rather than a single molecular target like an enzyme or receptor, it is characterized in drug development by the specific viral or host surface proteins these cells express.

Other names

EBV+ cellsEpstein-Barr virus-positive cellsHuman herpesvirus 4-infected cellsHHV-4 infected cells

Inhibition of viral DNA polymerase, antibody-dependent cellular cytotoxicity (ADCC) against B-cell markers, T-cell mediated cytolysis of cells presenting viral antigens (EBNA, LMP), and induction of apoptosis in transformed cells.